RU2020123217A -
Anti-SARS-CoV-2 virus agent Antiprovir
- Google Patents
Anti-SARS-CoV-2 virus agent Antiprovir
Download PDF
Info
Publication number
RU2020123217A
RU2020123217ARU2020123217ARU2020123217ARU2020123217ARU 2020123217 ARU2020123217 ARU 2020123217ARU 2020123217 ARU2020123217 ARU 2020123217ARU 2020123217 ARU2020123217 ARU 2020123217ARU 2020123217 ARU2020123217 ARU 2020123217A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андрей Александрович Иващенко, Александр Васильевич Иващенко, Николай Филиппович Савчук, Алёна Александровна Иващенко, Владимир Григорьевич Логинов, Михаил ТОПРfiledCriticalАндрей Александрович Иващенко
Priority to RU2020123217ApriorityCriticalpatent/RU2020123217A/en
Priority to EA202000347Aprioritypatent/EA202000347A1/en
Priority to PCT/RU2021/000019prioritypatent/WO2021221537A1/en
Publication of RU2020123217ApublicationCriticalpatent/RU2020123217A/en
Publication of RU2020123217A3publicationCriticalpatent/RU2020123217A3/ru
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Claims (4)
1. Способ профилактики и лечения SARS-CoV-2 (COVID-19) инфекций у пациентов, заключающийся во введении пациенту лекарственного средства Антипровир.1. A method for the prevention and treatment of SARS-CoV-2 (COVID-19) infections in patients, which consists in administering Antiprovir to the patient.2. Способ по п.1, заключающийся во внутривенной терапии.2. The method according to claim 1, which consists in intravenous therapy.3. Способ по п.1, заключающийся в спрей-терапии.3. The method according to claim 1, which consists in spray therapy.4. Способ по пп. 1-3, заключающийся во введении пациенту лекарственного средства Антипровир в дозе от 300 КИЕ до 150000 КИЕот 2-х до 4-х раз в день в течение от 5-ти до 14-ти дней. 4. The method according to paragraphs. 1-3, which consists in administering to the patient the drug Antiprovir at a dose of 300 CIE to 150,000 CIE2 to 4 times a day for 5 to 14 days.